Enveric Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering a novel class of aminated tryptamine derivatives. These compounds, designed to address psychiatric and neurological disorders, are non-hallucinogenic psychedelic analogs and represent a first-in-class approach to mental health treatments. The patented molecules, developed through Enveric's proprietary discovery platform, promise improved safety and scalability, with applications for conditions like depression and anxiety without hallucinogenic side effects.